Literature DB >> 17973318

Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy.

Shakeel Modak1, Neeta Pandit-Taskar, Brian H Kushner, Kim Kramer, Peter Smith-Jones, Steven Larson, Nai-Kong V Cheung.   

Abstract

Radioiodinated metaiodobenzylguanidine [(131)I-MIBG] is commonly used to treat resistant neuroblastoma or metastatic pheochromocytoma [MP] with little non-hematopoietic toxicity. We describe here transient sialoadenitis, a previously unreported complication. Ten patients [9 neuroblastoma and 1 MP] received 12-18 mCi/kg of (131)I-MIBG. Five patients had bilateral parotid swelling, two with associated buccal discomfort within 24 hr of injection which subsided within 48 hr. Grade 3 or 4 serum amylase elevation was documented in 8/8 patients tested [median 1,336; range: 576-8,830 U/L] which normalized [25-125 U/L] within 4-14 [median 5.5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17973318     DOI: 10.1002/pbc.21391

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.

Authors:  Alekist Quach; Lingyun Ji; Vikash Mishra; Aimee Sznewajs; Janet Veatch; John Huberty; Benjamin Franc; Richard Sposto; Susan Groshen; Denice Wei; Paul Fitzgerald; John M Maris; Gregory Yanik; Randall A Hawkins; Judith G Villablanca; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2010-09-09       Impact factor: 3.167

2.  Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine (mIBG).

Authors:  Antonio J Lopez Quiñones; Leticia Salvador Vieira; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2022-02-22       Impact factor: 3.579

Review 3.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

4.  Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Authors:  Shakeel Modak; Pat Zanzonico; Jorge A Carrasquillo; Brian H Kushner; Kim Kramer; Nai-Kong V Cheung; Steven M Larson; Neeta Pandit-Taskar
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

Review 5.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

6.  Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

Authors:  Bae P Chu; Christopher Horan; Ellen Basu; Lawrence Dauer; Matthew Williamson; Jorge A Carrasquillo; Neeta Pandit-Taskar; Shakeel Modak
Journal:  Pediatr Blood Cancer       Date:  2016-01-15       Impact factor: 3.167

7.  Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.

Authors:  Antonio J López Quiñones; David J Wagner; Joanne Wang
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

8.  Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

Authors:  Megan Trieu; Steven G DuBois; Elizabeth Pon; Lorenzo Nardo; Randall A Hawkins; Araz Marachelian; Clare J Twist; Julie R Park; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2015-10-27       Impact factor: 3.167

Review 9.  Current Consensus on I-131 MIBG Therapy.

Authors:  Daiki Kayano; Seigo Kinuya
Journal:  Nucl Med Mol Imaging       Date:  2018-05-03

Review 10.  Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.

Authors:  Daiki Kayano; Seigo Kinuya
Journal:  ScientificWorldJournal       Date:  2015-03-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.